NCT07128550

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Vir Biotechnology, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide

Conditions

• Viral Hepatitis

Interventions

Type	Name	Description
DRUG	Tobevibart	Tobevibart administered by subcutaneous injection
DRUG	Elebsiran	Elebsiran administered by subcutaneous injection
DRUG	Bulevirtide	Bulevirtide administered by subcutaneous injection

Timeline

• Start date: 2025-07-30
• Primary completion: 2026-12-01
• Completion: 2031-07-01
• First posted: 2025-08-19
• Last updated: 2026-03-31

Locations

36 sites across 7 countries: Austria, France, Germany, Italy, Romania, Spain, United Kingdom

Regulatory

• FDA-regulated drug study